SCHEMBL1703701

SCHEMBL1703701

CCC(N)c1nc2ccsc2c(=O)n1-c1cccc(OC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
USP2 O75604 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
ALDH1A1 P00352 3/20 0.42
PIK3CD O00329 2/20 0.42
MAPT P10636 2/20 0.42
RXFP1 Q9HBX9 2/20 0.42
POLB P06746 1/20 0.41
LMNA P02545 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
KIF11 P52732 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP1A2 P05177 1/20 0.40
HPGD P15428 2/20 0.40
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MALT1 Q9UDY8 1/20 0.39
GNRHR P30968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1703762 0.88 GAA (0.47) GAAL3MBTL1USP2SMN1; SMN2ALDH1A1
SCHEMBL1703433 0.87 ALDH1A1 (0.44) GAAL3MBTL1SMN1; SMN2ALDH1A1PIK3CD
SCHEMBL1703546 0.86 ALDH1A1 (0.57) GAAL3MBTL1SMN1; SMN2ALDH1A1PIK3CD
SCHEMBL1703684 0.81 ALDH1A1 (0.43) GAAL3MBTL1SMN1; SMN2ALDH1A1PIK3CD
SCHEMBL1703448 0.80 POLB (0.51) GAAL3MBTL1SMN1; SMN2ALDH1A1PIK3CD
SCHEMBL4229663 0.77 USP2 (0.53) GAAUSP2SMN1; SMN2ALDH1A1MAPT
SCHEMBL1704260 0.77 PIK3CD (0.49) PIK3CD
SCHEMBL1703695 0.76 PIK3CD (0.49) L3MBTL1SMN1; SMN2ALDH1A1PIK3CDMAPT
SCHEMBL4237075 0.75 USP2 (0.53) GAAUSP2SMN1; SMN2ALDH1A1MAPT
SCHEMBL1703808 0.74 POLB (0.45) GAAL3MBTL1SMN1; SMN2ALDH1A1PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2441768-A1 Thienopyrimidinones for treatment of inflammatory disorders and cancers Eli Lilly & Co. (US) 2012-04-18 EP disclosed
US-20100216820-A1 THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS ICOS CORPORATION 2010-08-26 US disclosed
EP-2097422-A1 THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS Eli Lilly & Co. (US) 2009-09-09 EP disclosed
WO-2008064018-A1 THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS ELI LILLY & CO. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216820-A1 THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS PIK3CA, PIK3CD, PIK3CB GAA 4020/4885L3MBTL1 3358/4885USP2 2203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.